CD19 and neoplasm: In turn, in 17/23 (71%) leukemia/lymphoma cases, hematopoietic tumor cells were identified, including 14/17 (82%) CD45+ leukemias/lymphomas and 3/17 (18%) CD19+ cyCD79a+ CD45− B-LL samples (Figure 2).